Published in Proc Natl Acad Sci U S A on December 01, 1986
Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest (1991) 2.08
Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol (2007) 2.07
The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J Virol (1992) 1.95
Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J Virol (2003) 1.65
Human liver plasma membranes contain receptors for the hepatitis B virus pre-S1 region and, via polymerized human serum albumin, for the pre-S2 region. J Virol (1989) 1.61
DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci U S A (1995) 1.60
Immunogenicity of peptide fusions to hepatitis B virus core antigen. Proc Natl Acad Sci U S A (1989) 1.57
Production of infectious hepatitis delta virus in vitro and neutralization with antibodies directed against hepatitis B virus pre-S antigens. J Virol (1992) 1.45
Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope. Proc Natl Acad Sci U S A (1988) 1.41
Vaccine engineering: enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes. Proc Natl Acad Sci U S A (1989) 1.39
Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination. Infect Immun (1994) 1.31
DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci U S A (1996) 1.28
Epitope mapping of neutralizing monoclonal antibodies against duck hepatitis B virus. J Virol (1989) 1.13
Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. Med Microbiol Immunol (2015) 1.10
Transferrin receptor mediates uptake and presentation of hepatitis B envelope antigen by T lymphocytes. J Exp Med (1992) 1.09
Hepatitis B virus (HBV) binding factor in human serum: candidate for a soluble form of hepatocyte HBV receptor. J Virol (1993) 1.08
Fibronectin of human liver sinusoids binds hepatitis B virus: identification by an anti-idiotypic antibody bearing the internal image of the pre-S2 domain. J Virol (1995) 1.06
Hepatitis B virus surface antigen binds to apolipoprotein H. J Virol (1994) 1.04
The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man. J Clin Invest (1989) 1.02
Construction of a plasmid for expression of foreign epitopes as fusion proteins with subunit B of Escherichia coli heat-labile enterotoxin. Infect Immun (1989) 1.00
Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immunol (2014) 0.98
Virus-neutralizing monoclonal antibody to a conserved epitope on the duck hepatitis B virus pre-S protein. J Virol (1990) 0.98
Male-specific W4P/R mutation in the pre-S1 region of hepatitis B virus, increasing the risk of progression of liver diseases in chronic patients. J Clin Microbiol (2013) 0.97
Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of Salmonella. Proc Natl Acad Sci U S A (1989) 0.94
Mutations in preS genes of genotype C hepatitis B virus in patients with chronic hepatitis B and hepatocellular carcinoma. J Gastroenterol (2007) 0.94
Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites. Infect Immun (1988) 0.88
Expression of hepatitis B virus middle and large surface antigen genes in Saccharomyces cerevisiae. J Virol (1987) 0.83
Male-specific hepatitis B virus large surface protein variant W4P potentiates tumorigenicity and induces gender disparity. Mol Cancer (2015) 0.82
Primary and secondary prevention of liver cancer caused by HBV. Front Biosci (Schol Ed) (2010) 0.82
Removing N-terminal sequences in pre-S1 domain enhanced antibody and B-cell responses by an HBV large surface antigen DNA vaccine. PLoS One (2012) 0.81
Production and secretion in Escherichia coli of hepatitis B virus pre-S2 antigen as fusion proteins with beta-lactamase. Appl Environ Microbiol (1990) 0.77
Phage display creates innovative applications to combat hepatitis B virus. World J Gastroenterol (2014) 0.77
Hepatitis B virus preS1 deletion is related to viral replication increase and disease progression. World J Gastroenterol (2015) 0.77
Validation of cross-genotype neutralization by hepatitis B virus-specific monoclonal antibodies by in vitro and in vivo infection. PLoS One (2015) 0.76
Liver disease. Postgrad Med J (1994) 0.76
Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection. J Gastroenterol (2016) 0.76
Genetic variation of occult hepatitis B virus infection. World J Gastroenterol (2016) 0.75
Viral hepatitis. Gut (1991) 0.75
Elucidation of the early infection machinery of hepatitis B virus by using bio-nanocapsule. World J Gastroenterol (2016) 0.75
Hepatology. Postgrad Med J (1991) 0.75
Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci U S A (1981) 32.98
Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature (1979) 15.42
Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med (1980) 9.34
Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol (1984) 6.90
Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature (1982) 5.50
The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw. Nucleic Acids Res (1983) 5.41
New procedures for preparation and isolation of conjugates of proteins and a synthetic copolymer of D-amino acids and immunochemical characterization of such conjugates. Biochemistry (1979) 5.02
Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol (1978) 5.02
Biology of hepatitis B virus. Science (1981) 4.93
The heterogeneity of Australia antigen. J Infect Dis (1971) 4.35
Solid-phase peptide synthesis. Adv Enzymol Relat Areas Mol Biol (1969) 4.30
Chemically synthesized peptides predicted from the nucleotide sequence of the hepatitis B virus genome elicit antibodies reactive with the native envelope protein of Dane particles. Proc Natl Acad Sci U S A (1981) 4.26
Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature (1982) 3.82
Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides. Nature (1983) 3.35
Structural relationships between minor and major proteins of hepatitis B surface antigen. J Virol (1983) 3.09
Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HBsAg peptides. Nature (1982) 3.01
Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis (1977) 2.80
Detection of additional antigenic determinants of hepatitis B antigen. J Immunol (1972) 2.57
Hepatitis B virus vaccine: identification of HBsAg/a and HBsAg/d but not HBsAg/y subtype antigenic determinants on a synthetic immunogenic peptide. Proc Natl Acad Sci U S A (1982) 2.52
A hepatitis B surface antigen polypeptide (P31) with the receptor for polymerized human as well as chimpanzee albumins. Gastroenterology (1983) 2.49
Human hepatitis B vaccine from recombinant yeast. Nature (1984) 2.46
Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science (1985) 2.18
Hepatitis B virus contains pre-S gene-encoded domains. Nature (1985) 2.02
Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med (1984) 1.93
A polypeptide containing 55 amino acid residues coded by the pre-S region of hepatitis B virus deoxyribonucleic acid bears the receptor for polymerized human as well as chimpanzee albumins. Gastroenterology (1984) 1.90
Anti-influenza response achieved by immunization with a synthetic conjugate. Proc Natl Acad Sci U S A (1982) 1.85
Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the a determinant. Proc Natl Acad Sci U S A (1982) 1.81
Location and chemical synthesis of a pre-S gene coded immunodominant epitope of hepatitis B virus. Science (1984) 1.63
A receptor for polymerized human and chimpanzee albumins on hepatitis B virus particles co-occurring with HBeAg. Gastroenterology (1979) 1.63
A 49,000-dalton polypeptide bearing all antigenic determinants and full immunogenicity of 22-nm hepatitis B surface antigen particles. J Immunol (1980) 1.50
Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA. JAMA (1984) 1.33
Clinical evaluation of a recombinant hepatitis B vaccine. Lancet (1984) 1.33
Identification of hepatitis B virus polypeptides encoded by the entire pre-s open reading frame. J Virol (1985) 1.23
Large-scale isolation of Dane particles from plasma containing hepatitis B antigen and deomnstration of circular double-stranded DNA molecule extruding directly from their cores. J Immunol (1976) 1.04
A glycopeptide containing 15 amino acid residues derived from hepatitis B surface antigen particles: demonstration of immunogenicity to raise anti-HBs in mice. Mol Immunol (1982) 1.00
Demonstration of albumin receptors on isolated human hepatocytes by light and scanning electron microscopy. Hepatology (1983) 0.97
Low molecular weight (7s) immunoglobulin M antibody against hepatitis B core antigen in the serum for differentiating acute from persistent hepatitis B virus infection. Gastroenterology (1984) 0.94
Immunogenicity of recombinant yeast hepatitis B vaccine. Lancet (1985) 0.89
Albumin binding sites of human hepatocytes. Liver (1983) 0.88
Immune response to a heat-inactivated hepatitis B vaccine in patients undergoing hemodialysis. Enhancement of the response by increasing the dose of hepatitis B surface antigen from 3 to 27 micrograms. Arch Intern Med (1985) 0.88
Seroconversion rates with hepatitis B vaccine. Ann Intern Med (1984) 0.86
Low immune responses to hepatitis B vaccination among healthy subjects. Lancet (1985) 0.81
Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun (1999) 14.25
CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature (1997) 10.49
Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol (2000) 9.85
Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation (2000) 6.96
Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med (1996) 6.01
Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol (1992) 5.93
Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol (1988) 5.75
The 5'-terminal sequence of the hepatitis C virus genome. Jpn J Exp Med (1990) 5.46
The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell (1992) 5.39
Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation (2000) 5.36
A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun (1997) 5.25
PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes (2001) 5.18
Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes. Virology (1992) 5.16
Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions. J Gen Virol (1991) 5.03
Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell (1991) 4.98
A cyclic nucleotide-gated conductance in olfactory receptor cilia. Nature (1987) 4.81
STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J (1999) 4.55
Clinical application of transvenous mitral commissurotomy by a new balloon catheter. J Thorac Cardiovasc Surg (1984) 4.45
Abdominal fat: standardized technique for measurement at CT. Radiology (1999) 4.25
Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med (1997) 4.06
e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med (1976) 4.01
Detection of the GBV-C hepatitis virus genome in serum from patients with fulminant hepatitis of unknown aetiology. Lancet (1995) 3.99
Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun (1984) 3.70
Immunochemical structure of hepatitis B e antigen in the serum. J Immunol (1983) 3.50
Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J Cell Biol (1999) 3.43
Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin- mediated cell-cell adhesion. Science (1998) 3.39
Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol (2001) 3.32
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A (1998) 3.23
Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science (1999) 3.22
Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology (1992) 3.22
Leukaemia disease genes: large-scale cloning and pathway predictions. Nat Genet (1999) 3.19
Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A (1993) 3.16
Infection with hepatitis GB virus C in patients on maintenance hemodialysis. N Engl J Med (1996) 3.13
The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res (1995) 3.04
Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med (1996) 3.02
A high-speed atomic force microscope for studying biological macromolecules. Proc Natl Acad Sci U S A (2001) 2.97
The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell (2001) 2.97
Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol (1993) 2.90
Yeast KEX2 genes encodes an endopeptidase homologous to subtilisin-like serine proteases. Biochem Biophys Res Commun (1988) 2.89
Detection of Australia antigen by means of immune adherence haemagglutination test. Vox Sang (1971) 2.88
Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis (1977) 2.80
Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5'-noncoding region. Jpn J Exp Med (1990) 2.72
Small, stable shuttle vectors based on the minimal pVS1 replicon for use in gram-negative, plant-associated bacteria. Mol Plant Microbe Interact (2000) 2.71
Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. Lancet (1999) 2.71
Activation of mouse complement by different classes of mouse antibody. Immunology (1979) 2.68
Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein. Genes Dev (2000) 2.65
Defective immune-adherence (C3b) receptor on erythrocytes from patients with systemic lupus erythematosus. Lancet (1981) 2.64
Trithorax and dCBP acting in a complex to maintain expression of a homeotic gene. Science (2001) 2.61
An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res (2000) 2.59
Meis proteins are major in vivo DNA binding partners for wild-type but not chimeric Pbx proteins. Mol Cell Biol (1997) 2.57
Demonstration of hepatitis B e antigen in the core of Dane particles. J Immunol (1979) 2.56
Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol (1992) 2.53
The Arabidopsis HKT1 gene homolog mediates inward Na(+) currents in xenopus laevis oocytes and Na(+) uptake in Saccharomyces cerevisiae. Plant Physiol (2000) 2.53
The C-terminal SET domains of ALL-1 and TRITHORAX interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex. Proc Natl Acad Sci U S A (1998) 2.52
Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med (1999) 2.51
A hepatitis B surface antigen polypeptide (P31) with the receptor for polymerized human as well as chimpanzee albumins. Gastroenterology (1983) 2.49
A tumor promoter induces rapid and coordinated reorganization of actin and vinculin in cultured cells. J Cell Biol (1984) 2.46
Genetic and molecular characterization of the Pseudomonas plasmid pVS1. Plasmid (1984) 2.44
Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci (1999) 2.44
Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality. Oncogene (2001) 2.42
Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol (1994) 2.41
Ampulla cardiomyopathy ('Takotusbo' cardiomyopathy)--reversible left ventricular dysfunction: with ST segment elevation. Jpn Circ J (2000) 2.39
Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann Intern Med (1994) 2.38
Complexity of terminal airspace geometry assessed by lung computed tomography in normal subjects and patients with chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A (1999) 2.38
Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci U S A (1986) 2.37
Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology (1992) 2.37
Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process. Lancet (1990) 2.35
Preparation of bioactive Ti and its alloys via simple chemical surface treatment. J Biomed Mater Res (1996) 2.34
Emerging multipotent aspects of hepatocyte growth factor. J Biochem (1996) 2.34
Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem (1999) 2.33